enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Up 32.4% in December

enGene Holdings Inc. (NASDAQ:ENGN) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 1,497,488 shares, a growth of 32.4% from the December 15th total of 1,130,950 shares. Based on an average trading volume of 268,316 shares, the short-interest ratio is presently 5.6 days. Currently, 2.5% of the company’s stock are sold short. Currently, 2.5% of the company’s stock are sold short. Based on an average trading volume of 268,316 shares, the short-interest ratio is presently 5.6 days.

Institutional Trading of enGene

A number of hedge funds have recently modified their holdings of ENGN. Affinity Asset Advisors LLC acquired a new position in enGene in the 2nd quarter valued at about $280,000. Citadel Advisors LLC boosted its holdings in shares of enGene by 153.3% during the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock worth $399,000 after acquiring an additional 35,327 shares during the period. PFS Partners LLC boosted its holdings in shares of enGene by 22.2% during the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after acquiring an additional 2,000 shares during the period. Hudson Bay Capital Management LP acquired a new position in shares of enGene in the third quarter valued at approximately $76,000. Finally, Millennium Management LLC increased its stake in shares of enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after purchasing an additional 7,472 shares during the period. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Trading Up 1.0%

enGene stock opened at $9.31 on Friday. The stock has a 50-day simple moving average of $8.35 and a 200 day simple moving average of $6.52. The stock has a market capitalization of $623.63 million, a P/E ratio of -4.07 and a beta of -0.29. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30. enGene has a 52 week low of $2.65 and a 52 week high of $11.14.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). Analysts expect that enGene will post -1.56 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ENGN shares. Morgan Stanley increased their target price on enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Wednesday, November 12th. Citizens Jmp lifted their target price on enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 12th. Raymond James Financial upgraded enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 target price on the stock in a research note on Tuesday, November 11th. Citigroup reaffirmed a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. Finally, Oppenheimer reissued an “outperform” rating and issued a $33.00 price objective (up previously from $30.00) on shares of enGene in a research report on Wednesday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.38.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.